Abbreviations used: CFSE, carboxyfluorescein succinimidyl ester; VACV, vaccinia virus.
IntroductIon
DCs are a specialized population of immune cells that excel in antigen presentation and induce adaptive immune responses (Mellman and Steinman, 2001) . Like other cells, DCs can pre sent peptides derived from cytosolic antigens loaded on MHC class I to CD8 + T cells and to both endogenous and exoge nous antigens bound to MHC class II molecules for recogni tion by CD4 + T cells. In addition, DCs can take up exogenous antigens and process and load them onto MHC class I mole cules to be presented to CD8 + T cells, a process called antigen "crosspresentation" (the resulting induction of a CD8 + T cell response is referred to as "crosspriming"; Joffre et al., 2012) .
Several pathways of antigen crosspresentation that involve membrane trafficking through different intracellu lar compartments were reported in cultured DCs (Savina et al., 2006 (Savina et al., , 2009 Jancic et al., 2007; Cebrian et al., 2011; NairGupta et al., 2014; Alloatti et al., 2015) . One of the de scribed crosspresentation pathways requires transfer of ER resident proteins, including the machinery for MHC class I loading with peptides (TAP1/2 transporters, tapasin, calretic ulin, etc.), to the endocytic and phagocytic pathways, a traf fic step controlled by the SNA RE family member Sec22b (Cebrian et al., 2011) .
The actual contribution of different antigen cross presentation pathways to immune responses in vivo re mains unclear. The K. Murphy group (Hildner et al., 2008) has shown that certain subsets of crosspresenting DCs (i.e., Batf3dependent DCs) have a critical role in antiviral im mune responses and in the rejection of established solid tumors by CD8 + T cells. Recently, the R. Germain group (Castellino et al., 2006; Eickhoff et al., 2015) showed that CD8 + DCs act as "cellular platforms" to support CD4 + T cell help for CD8 + responses, a role that goes beyond their crosspresentation capacities. In contrast, increasing examples of CD8 − DCs crosspresenting antigen in vivo are being re ported (den Haan et al., 2000; Kamphorst et al., 2010) . The actual contribution of antigen crosspresentation by DCs to specific immune responses is, therefore, a critical unknown. This is particularly true in the context of immunother apies that attempt to harness the immune system to treat can cer, including those using checkpoint inhibitors. Expression of programmed cell death protein1 (PD1) on the surface of tumorspecific lymphocytes, and interaction with its cor responding ligands (PDL1 and PDL2, respectively) on the tumor or antigenpresenting target cells is a key immune checkpoint that inhibits T cell function. Seminal studies in mouse models of cancer and diverse clinical studies have cd8 + t cells mediate antigen-specific immune responses that can induce rejection of solid tumors. In this process, dendritic cells (dcs) are thought to take up tumor antigens, which are processed into peptides and loaded onto MHc-I molecules, a process called "cross-presentation." neither the actual contribution of cross-presentation to antitumor immune responses nor the intracellular pathways involved in vivo are clearly established because of the lack of experimental tools to manipulate this process. to develop such tools, we generated mice bearing a conditional dc-specific mutation in the sec22b gene, a critical regulator of endoplasmic reticulum-phagosome traffic required for cross-presentation. dcs from these mice show impaired cross-presentation ex vivo and defective cross-priming of cd8 + t cell responses in vivo. these mice are also defective for antitumor immune responses and are resistant to treatment with anti-Pd-1. We conclude that Sec22b-dependent cross-presentation in dcs is required to initiate cd8 + t cell responses to dead cells and to induce effective antitumor immune responses during anti-Pd-1 treatment in mice.
Critical role for Sec22b-dependent antigen crosspresentation in antitumor immunity
established that mAbs blocking the PD1/PDL1 pathway, as well as other checkpoints, such as CTLA4, can unleash the immune system to fight cancer (Leach et al., 1996; Iwai et al., 2002) . These therapies can mediate tumor regression in patients with metastatic melanoma, non-small cell lung cancer and renal cell carcinoma, among others (Hodi et al., 2010; Topalian et al., 2012; Lebbé et al., 2014) . In mice, anti immune, checkpointbased treatments have been analyzed with success in several tumor models. The Melero labora tory (SánchezPaulete et al., 2016) has shown recently that Batf3dependent DCs actively contribute to rejection of tu mors during anti-PD1 and antiCD137 immunotherapies.
To define the contribution of antigen crosspresentation to CD8 + T cell responses, we generated a mouse line in which the expression of Sec22b was conditionally depleted in DCs. Reduced Sec22b expression in DCs impairs anti gen crosspresentation and crosspriming of cellassociated antigens in vivo. Sec22bdefective mice also failed to mount effective antitumor immune responses, to control the growth of immunogenic tumors, and to respond to anti-PD1-based immunotherapy. These results show that Sec22bdependent antigen crosspresentation is required during crosspriming of CD8 + T cell responses with dead cell-derived antigens and for anti-checkpointtumor immunotherapy in mice.
reSultS and dIScuSSIon
To investigate the role of Sec22bdependent crosspresentation in vivo, we generated floxed sec22b knockin mice and crossed them to CD11cspecific Credeleter mice (Caton et al., 2007) . We thus obtained mice bearing a selective de letion of the sec22b gene in DCs (Sec22b −/− ). As controls, throughout the study, we used littermates expressing the Cre recombinase, and WT alleles of the sec22b gene (Sec22b +/+ ). Western blot analysis of splenic CD11c + cells isolated by two rounds of selection (negative and then positive) confirmed that Sec22b expression was reduced in primary DCs puri fied from Sec22b −/− , but not Sec22b +/+ mice ( Fig. 1 A, top) . Sec22b expression in peritoneal macrophages (Fig. 1, top) , as well as in splenic B and T cells ( Fig. 1 A, bottom) was not affected, confirming that Sec22b −/− mice bear a conditional defect in Sec22b expression in DCs.
Phenotypic analysis of DC subsets in spleen ( Fig. 1 B ) and lungs ( Fig. 1 C) from Sec22b −/− and Sec22b +/+ mice did not show any significant differences, neither in the composi tion of cell subpopulations nor in total cells numbers. Neither the percentages nor the numbers of other immune cell sub populations from spleen, thymus, blood, lungs, and different lymph nodes were affected in Sec22bdefective mice (Fig. S1, A-F). Sec22b depletion did not modify the capacity of splenic CD8 + DCs to respond to different stimuli, such as LPS, IFNγ, and TNF, as measured by expression of MHC II and CD86 ( Fig. S1 G) . We also confirmed by Western blot that Sec22b expression was reduced in BMDCs generated from Sec22b −/− mice, as compared with littermates ( Fig. 1 D) . Sec22b depletion did not affect the percentages of CD11c high CD11b high cells in culture (Fig. 1 E, left) or LPSmediated activation, as detected by expression of costimulatory mole cules, (CD40, CD80, and CD86 and MHC class II; Fig. 1 E, right). IFNγ and TNF induced an equivalent augment in the expression of CD86 and MHC II in both Sec22b +/+ and Sec22b −/− mice ( Fig. S1 H) . Finally, levels of MHC class I expression (both H2K b and H2D b ) were not affected by Sec22b depletion (Fig. 1 F) . Therefore, defective Sec22b ex pression in DCs does not affect their development, survival, or activation capacity in vitro or in vivo.
As a first analysis pertaining to DC function, we as sessed the phagocytic and endocytic capacities of BMDCs. Both endocytosis and phagocytosis were similar in bone marrowderived DCs (BMDCs) generated from Sec22b +/+ or Sec22b −/− mice (Fig. 2, A and B , respectively). To inves tigate whether Sec22bdefective DCs bear a defect in an tigen crosspresentation, we first generated BMDCs from Sec22b −/− and control littermates. As shown in Fig. 2 C, BMDCs from Sec22bdeficient mice bear a partial defect in crosspresentation of soluble and beadbound OVA, as de tected by B3Z activation (top; Kurts et al., 1996) , CD69 and CD25 expression (middle), and proliferation of OTI CD8 + T cells, measured by dilution of carboxyfluorescein succin imidyl ester (CFSE; bottom). The synthetic MHC class Irestricted OVA peptide (SII NFE KL) was presented with equal efficacy by BMDCs generated from Sec22b −/− and Sec22b +/+ mice ( Fig. 2 C, left ).
In addition, as an alternative source of antigen, we used vaccinia virus (VACV)-OVA-infected RAW macrophages (H2K d ; RAWVACV), which transmit virus and infect DCs that can direct present antigens in H2K b MHC class I mol ecules. Alternatively, infected RAW cells were treated with UV light (RAWVACVUV) to inactivate the virus, block ing direct infection of DCs and leaving available only the crosspresentation route, as previously described (Iborra et al., 2012) . We also used uninfected RAW cells treated with UV (RAWUV) to test antigen specificity. BMDCs gener ated from Sec22b +/+ and Sec22b −/− mice were exposed to VACVinfected or control cells for 4 h and used to stimulate preactivated OTI T cells or CD8 + T cells purified from WT mice previously infected with VACV WT. Production of IFNγ by OTI ( Fig. 2 D , top) or vacciniaspecific effector CD8 + T cells ( Fig. 2 D, bottom) was not affected by Sec22bdepletion in DCs directly infected with the virus (Fig. 2 D, left) but was impaired in DCs cocultured with RAWVACVUV ( Fig. 2 D , right) . Moreover, MHC class II-restricted antigen presenta tion, as measured by activation and proliferation of OTII CD4 + OVAspecific TCR transgenic T cells, was not affected in Sec22bdeficient BMDCs (Fig. 2 E) . Therefore, in agree ment with our previous results in Sec22b knockdown BMDCs (Cebrian et al., 2011) , BMDCs generated from Sec22bdefective mice display impaired crosspresentation, but conventional MHC class I and II antigen presentation is not affected.
Similar to BMDCs, CD11c + splenic DCs isolated from Sec22b −/− mice also crosspresent OVA to CD8 + T cells less efficiently than do those purified from littermates ( Fig. 3 A) , whereas MHC class II-restricted presentation to CD4 + T cells is unaffected ( Fig. 3 B) . To investigate the role of Sec22b depletion in DCs in crosspriming, we first tested whether CD8 + T cells responses were normal in Sec22b −/− mice. We immunized Sec22b +/+ and Sec22b −/− mice with IFACpGSII NFE KL in the footpad and analyzed antiOVA and antiSII NFE KL responses by IFNγ ELI SPOT in drain ing popliteal and inguinal lymph nodes. CD8 + T cells from Sec22b +/+ and Sec22b −/− were equally restimulated with SII NFE KL ( Fig. S2 A) , whereas the restimulation with OVA was impaired in Sec22b −/− mice. These results indicate that Sec22b −/− mice have a functional CD8 + T cells compartment and that the SII NFE KLspecific repertoire is normal.
To determine whether the defect in antigen crosspresentation in Sec22bdepleted DCs results in defective crosspriming in vivo, we injected necroptotic, OVAexpressing 3T3RIPK3OVA cells (Yatim et al., 2015) subcutaneously. The endogenous CD8 + T cell response against OVA was an alyzed using MHCI multimers (Yatim et al., 2015) after 9 d ( Fig. 3 C) . In Sec22b −/− mice, the endogenous cytotoxic CD8 + T cell response was significantly decreased from 2.134 ± 0.2835 to 0.6381 ± 0.1887%, as compared with control littermates (Fig. 3 D for gating strategy; Fig. 3 E) . The propor tion of migratory and resident DCs in lymph nodes was not affected by Sec22 depletion (Fig. 3 F, left, for gating; middle, for percentages; right, for cell numbers), indicating that the differences in crosspriming capacity are not the consequence of impaired migration capacity of Sec22b −/− DCs from the pe riphery. In addition, the number and percentages of the putative crosspresenting subsets CD8αα + resident DCs and CD103 + migratory DCs were not modified by depletion of Sec22b (Fig.  S2 , B and C). We conclude that crosspriming of dead cell-as sociated antigens in vivo requires Sec22b expression in DCs. The results presented thus far indicate that Sec22b −/− mice represent a suitable model to investigate the contribu tion of antigen crosspresentation to immune responses. To evaluate the role of crosspresentation in antitumor immu nity, we first analyzed the growth of a highly immunogenic OVAexpressing tumor cell line, EG7 (Moore et al., 1988; Helmich and Dutton, 2001) . EG7 tumors grew faster in Sec22b −/− mice (Fig. 4, A and B ), causing decreased survival ( Fig. 4 C) , as compared with littermates. That insufficiency to control tumors correlated with impaired OVAspecific CD8 + T cell responses ( Fig. 4 D and Fig. S3 A) . These results sug gest that impaired crosspresentation of tumor antigens by Sec22deficient DCs causes reduced antitumor immune re sponses and exacerbated tumor growth.
To address the possible role of Sec22bdependent anti gen crosspresentation in tumor immunotherapy by check point blocking antibodies, we used a lessimmunogenic tumor, OVAsecreting MCA101 (Zeelenberg et al., 2008; Sedlik et al., 2014) . This tumor is well controlled by antibodies against CTLA4 or PD1 (Gubin et al., 2014) . Sec22b −/− and Sec22b +/+ mice were injected with tumor cells and received or did not receive anti-PD1 treatment, as described previously (Gubin et al., 2014) . As expected, treatment with anti-PD1 induced tumor rejection in Sec22b +/+ littermates (Fig. 4 E) . In contrast, Sec22b −/− mice failed to respond to anti-PD1 treat ment, both in terms of tumor growth and survival (Fig. 4 , F and G). Consistently, treatment with anti-PD1 induced an anti OVA immune response in littermates, but not in Sec22b −/− mice, when analyzed by T cell restimulation and subsequent secretion of IFNγ ( Fig. 4 H and Fig. S3 B) .
To further investigate the mechanism of resistance to anti-PD1, we measured IFNγ production and proliferation capacity of CD8 + T cells isolated from spleen (Fig. S3 C) and tumor ( Fig. S3 D) of mice bearing MCA101OVA tumors and treated with anti-PD1. CD8 + T cells from Sec22b −/− produce IFNγ and proliferate to the same extent as CD8 + T cells from control mice. Expression of PD1 in T cells from Sec22b +/+ and Sec22b −/− was similar (Fig. S3 E) . The expres sion of PDL1 and PDL2 in CD8 + and CD8 − /CD11b + DCs from spleen was not reduced in Sec22bdeficient DCs (Fig. S3 F) . These results show a critical, nonredundant role for Sec22bdependent antigen crosspresentation in the onset of efficient antitumor immune responses induced by checkpoint blockade. Although crosspriming of allogeneic antigens in vivo was reported >30 yr ago (Bevan, 1976) , the actual contribu tion of antigen crosspresentation (vs. other mechanisms such as crossdressing (Wakim and Bevan, 2011; Yewdell and Dolan, 2011) or Gap junction-mediated peptide transfer (Neijssen et al., 2005) to crosspriming is still unclear. In the case of crosspresentation, multiple intracellular pathways have been reported in vitro. Each of those pathways is under the con trol of master regulators that control key intracellular traffic steps specific for each pathway. Here, we developed tools to perform loss of function experiments for Sec22bdependent antigen crosspresentation in vivo. Our results show that Sec22bdependent antigen crosspresentation by DCs has a critical role in the crosspriming of cellassociated antigens and antitumor immune responses in vivo (even though we did not exhaustively investigate all of the cell populations that might express CD11c, notably activated B cells that can help priming CD8 + T cell responses). It is possible that alternative crosspresentation pathways independent of Sec22b exist, but their contribution to the priming of CD8 + T cell responses in vivo needs to be addressed. Our results show that the induc tion of tumorspecific CD8 + T cells by anti-PD1 requires Sec22b expression in DCs, suggesting that, in addition to act ing on effector cytotoxic T cells by releasing tumorimposed immunosuppression, anti-PD1 may also facilitate the prim ing of CD8 + T cells. Whether Sec22b turns out to be a suitable target to modulate antigen crosspresentation therapeutically will need to be addressed in future studies.
MaterIalS and MetHodS compounds and antibodies
For flow cytometry, the following antibodies were used: anti-CD69eFluor450 (clone H1.2F3, 48069182; eBioscience), anti-CD25FITC (clone 7D4, 553072; BD), anti-CD8a PerCPCy5.5 (clone 53-6.7, 45008182; eBioscience), anti-TCR vβ 5.1PE (clone MR94, 553190; BD), anti-CD4 PECy7 (clone RM45, 552775; BD), anti-CD19eFluor450 (clone 1D3, 480193; eBioscience), anti-CD3eFluor450 (clone 17A2, 48003280; eBioscience), anti-CD11cFITC (clone HL3, 553801; BD), anti-CD11bPerCPCyanine5.5 (clone M1/70, eBioscience #45011280), antiF4/80FITC (clone BM8, eBioscience #11480181), antiNKp46PE (clone 29A1.4, 12335180; eBioscience), anti-MHC I (H2Kb)FITC (clone AF688.5.5.3, 11595880; eBio science), anti-MHC II (Iab)eFluor450 (clone AF120.1, 48532080; eBioscience). For Western blot analysis, the antiSec22b antibody was purchased from Santa Cruz Bio technology, Inc. (29F7, sc101267), antiαactin from Sig maAldrich (A2066), and antigp96 from Enzo Life Sciences (spa850). For phenotypic analysis of immune cell populations CD4, CD8, CD25, CD44, CD62L, TCRb, and CD3 were used as T cell markers (in different fluorophores, depending on the tissue analyzed and the panel of antibodies used). B220 and CD19 were used as B cell markers. TCRγδ was used as the γδ T cell marker. NK1.1 and NKp46 were used as natural killer markers. Gr1 and Ly6G were used as granulo cyte/neutrophil markers. CD11c was generally used as a DC marker, with the exception of lungs: alveolar macrophages (CD11c high ) were discriminated from DCs by analyzing Siglec F expression. CD103, IAb, H2Kb, CD11b, CD8, CD40, and CD86 were used to analyze DCs phenotype (in different flu orophores). F4/80 and Ly6C were used as macrophage mark ers. As for the direct MHC I antigenpresentation analysis, antimouse antibodies to CD8α, CD44, and IFNγ were used as conjugates to PE, FITC, and APC, and were obtained from eBioscience. Anti-PDL1PE and anti-PDL2APC were purchased from eBioscience. cell lines and cell culture RAW264.7 macrophages (RAW) were grown in DMEM supplemented with 5 mM glutamine, penicillin, streptomycin, βmercaptoethanol (all from Invitrogen) and 10% heatinac tivated FBS (SigmaAldrich). CD8 + T cells were negatively selected using a cocktail of biotinconjugated antibodies (antiCD11c, B220, MHCII, CD4, NK1.1), followed by incubation with streptavidin microbeads (Miltenyi Biotec). Typical yields by FACS staining were >95% pure. Preacti vated OTI cells were obtained by culturing spleen cells from OTI transgenic mice (C57BL/6Tg(TcraTcrb)1100Mjb/J) with 10 −9 M of the peptide 257 SII NFE KL 264 from OVA for 5 d. At that time, ∼90% of the cells were CD8 + CD44 hi . The 3T3RIPK3OVA cells, expressing a nonsecretable form of OVA cells, were obtained from the Matthew Albert laboratory (Yatim et al., 2015) and were cultured in DMEM (Thermo Fisher Scientific) supplemented with 10% FBS (Biowest), 0.1 mM nonessential aa, 1 mM sodium pyruvate, 10 mM Hepes, and 50 µM βmercaptoethanol (all from Thermo Fisher Scientific). Necroptosis was induced by treatment with a specific drug ligand (AP20187, BB homodimerizer; Takara Bio Inc.). EG7 tumor cells were cultured in DMEM supple mented with 10% FBS (Lonza), as well as 100 IU/ml penicil lin, 100 µg/ml streptomycin, 2 mM GlutaMAX, and 50 µM βmercaptoethanol (all from Thermo Fisher Scientific). MCA101 OVAsecreting cells were grown in RPMI1640 containing 10% heatinactivated FBS (Biowest), 100 IU/ml penicillin, 100 µg/ml streptomycin, 2 mM GlutaMAX, and 50 µM βmercaptoethanol (all from Thermo Fisher Scien tific), as well as hygromycin B 1 mg/ml (Gibco) for selection. All cell lines were tested as mycoplasmanegative by PCR.
dc activation
Maturation of BMDCs was induced by a 16h treatment with 100 ng/ml of ultrapure LPS from Escherichia coli 0111:B4 (InvivoGen) or, alternatively, with 100 ng/ml of TNF (Protein Service Facility, Inflammation Research Center) or IFNγ (Invitrogen). DC maturation was controlled by cellsurface expression of costimulatory molecules and MHC class II molecules using specific antibodies. Maturation of splenic CD11c + DCs was induced by a 4h treatment with 100 ng/ml of LPS, TNF, or IFNγ.
Virus strains
The rVACVOVA and VACV WR strains were gifts from Jonathan W. Yewdell and Jack R. Bennink (National Insti tutes of Health, Bethesda, MD). Stocks were grown in CV1 monolayers and used as clarified sonicated cell extracts.
Primary cell isolation and culture
BMDCs were produced by culturing the cells for 10 d in GMCSF-containing medium (as described in Alloatti et al., 2015) , with IMDM (SigmaAldrich and Thermo Fisher Sci entific) containing 10% heatinactivated FBS (Biowest), 100 IU/ml penicillin, 100 µg/ml streptomycin, 2 mM GlutaMAX, and 50 µM βmercaptoethanol (all from Thermo Fisher Sci entific). Supernatant from J558 plasmacytoma cells was used as the granulocyte macrophage colonystimulating factor source (Winzler et al., 1997) . To obtain splenic CD11c + DCs, each mouse spleen was injected with 2 ml of a digestion solu tion with 0.1 mg/ml Liberase (Roche), 0.1 mg/ml DNase I (Roche), 1× PenStrep in RPMI1640 (both from Thermo Fisher Scientific), following the Roche instructions, and was cut into small pieces and incubated for 25 min at 37°C. Re action was stopped by addition of complete medium. Spleens were passed through a cell strainer and centrifuged at 200× g for 5 min. After red blood cell lysis (SigmaAldrich), splenic DCs were isolated by performing one round of negative selection for CD11c + cells (using EasySep Mouse PanDC enrichment kit from STE MCE LL Technologies), followed by a round of positive selection using CD11c microbeads (Miltenyi Biotec), according to the manufacturer's instruc tions. In all experiments, purity of cells was >90%. For phe notypic characterization of immune cells, thymus and lungs were processed by digestion with Liberase/DNase I as stated above and was subsequently analyzed by flow cytometry. animals C57BL/6J mice and C57BL/6J recombination activat ing gene 1deficient OTI and OTII TCR (Vα2, Vβ5.1) transgenic mice were obtained from Charles River, Jan vier, and Centre de Distribution, Typage et Archive Ani mal. Mice were between 5 and 12 wk old. WT C57BL/6J mice for tumor experiments were always obtained from the aforementioned sources.
Sec22b Flox/Flox (see below) and control mice were orig inally produced at the Centre d'Immunologie de Marseille (the Malissen group) and were subsequently bred in the an imal facility of Institut Curie. CD11cCre transgenic mice were obtained from The Jackson Laboratory. All animal pro cedures were in accordance with the guidelines and regu lations of the Institut Curie veterinary department, and all mice used were <6 mo old.
targeting strategy for generation of Sec22b mice. A ge nomic fragment encompassing exon 2 and 4 of the sec22b gene was isolated from a BAC clone of B6 origin. Using ET recombination, loxP sites were introduced in the introns flanking the 5′ and 3′ ends of exon 2. The loxP site in the intron found at the 3′ end of exon 2 was abutted to a ftrneoRfrt cassette. The final targeting construct was abutted to a cassette coding for thymidine kinase and linearized with Pme1. eS clone selection. JM8.F6 C57BL/6N ES cells (Pettitt et al., 2009) were electroporated with the targeting vector. After se lection in G418 and ganciclovir, ES cell clones were screened for proper homologous recombination by Southern blot and PCR analysis. A neomycinspecific probe was used to ensure that adventitious, nonhomologous recombination events had not occurred in the selected ES clones. Properly recombined ES cells were injected into FVB blastocysts. Upon germline transmission, mice were then crossed to flipper mice to delete the frtflanked neoR cassette, and the resulting floxed Sec22b allele (official name B6Sec22b tm1Ciphe , called here Sec22b fl was identified by PCR of tail DNA. The pair of primers: sense 5′ATG GTA AAA AGC ACA CCA AAT ACT TTGC3′ and antisense 5′TGA GGT AAC CTT GAA GGC TAG AAGA3′ amplified a 600bp band in the case of the Sec22b WT allele and a 900bp band in the case of the Sec22b fl allele. The ex cised Sec22b fl allele generated a band of 300 bp (animals were screened for breeding and experiments based on the presence of this 300bp band). Considering that the phase of the in trons flanking exon 2 is asymmetrical, deletion of exon 2 re sults in an outofframe Sec22b allele.
Western blotting
Total cell lysates from BMDCs and splenic DCs were sub jected to 4-12% gradient gels (Thermo Fisher Scientific) or 10% and 12% gels and were separated by SDSPAGE. After transfer to nitrocellulose membranes, they were blocked and incubated with primary antibodies and peroxidaseconju gated secondary antibodies. Bound antibodies were revealed using the BM chemiluminescence blotting substrate (POD) from Roche or GE Healthcare, according to the manufactur ers' directions. The intensity of the bands was quantified by densitometry using Quantity One 4.6.6 software (BioRad Laboratories) and was expressed as arbitrary units.
antigen uptake assay Phagocytosis and the endocytic capacity of BMDCs were assessed using 3µm blue latex beads (Polysciences) and OVA Alexa Fluor 488 conjugate (O34781; Thermo Fisher Scientific), respectively.
Viral infections and virus titration.
Mice were infected intradermally in the ears with 5 × 10 4 PFU of the required VACV WR strain, as previously de scribed (Iborra et al., 2012) . antigen presentation assays Proliferation assay. DCs were incubated with Low Endo sol uble OVA from Worthington Biochemical Corporation (LS003061) or with 3µm beads coated with different ratios of OVA and BSA proteins (OVA 10 mg/ml alone; OVA 2.5 mg/ml-BSA 7.5 mg/ml; OVA 5 mg/ml-BSA 5 mg/ml; and BSA 10 mg/ml alone) or different concentrations of the con trol minimal peptide (OVA SII NFE KL for crosspresentation and OVA 323-339 for MHC II presentation). After 5 h, DCs were washed three times with PBS containing 0.1% (vol/vol) BSA and cocultured with purified CFSEOTI CD8 + for 3 d. For monitoring T cell proliferation, diminution of CFSE staining on TCR + CD8 + populations was measured by flow cytometry. t cell activation assay. DCs were incubated for 5 h with dif ferent concentrations of Low Endo soluble OVA from Worth ington Biochemical Corporation (LS003061) or with 3µm beads coated with different ratios of OVA and BSA proteins (as mentioned above). Minimal peptide OVA 257-264 was used as a control for the capacity of DCs to activate T cells. Next, DCs were washed three times with 0.1% (vol/vol) PBS/BSA, fixed with 0.008% (vol/vol) glutaraldehyde during 10 min at 4°C, washed twice with 0.2 M glycine and once with 0.1% (vol/vol) PBS/BSA, and finally, B3Z hybrid T cells were added. After 16 h, T cell activation was measured by detecting βgalactosidase activity by OD at 590 nm using chlorophenol redβdgalactopyranoside as the substrate for the reaction. The efficiency of antigen presentation on MHC I and MHC II was also evaluated using OTI (CD8 + ) and OTII (CD4 + T) cells, respectively. Where indicated, DCs were fixed with 0.008% of glutaraldehyde before T cell addition. The percent age of CD25 + CD69 + T cells was measured by flow cytometry after 16 h of coculture (MHC I and II-restricted peptides, OVA 257-264 and OVA 323-339 , respectively, were used as controls).
direct MHc class I antigen presentation and cross-presentation assay with VacV. DCs were stimulated by coculture with VACVOVA-infected RAW cells treated with or without UV irradiation to inactivate the virus. To test DC crosspresenting ability, RAW cells were irradiated with UVC (240 mJ/cm 2 ) either without exposure to VACVOVA (RAW UV) or after incubation with VACV for 4 h (RAWVACVUV). Alternatively, infected RAW cells were left unirradiated (RAWVACV) to allow direct infection of DCs. 16 h after UV irradiation, RAW cells were cocultured for 4 h with BMDCs generated from Sec22b +/+ and Sec22b −/− mice. To the cocultures, we then added CD8 + T cells purified from splenocytes of mice intradermally injected 7 d earlier with WR VACV, or preactivated OTI cells were added to the cul tures for 6 h; then, Brefeldin A (5 µg/ml; SigmaAldrich) was added for the last 4 h of culture. Cells were then stained with PEantiCD8α and FITCCD44, fixed in 4% PFA, and incu bated with APCantiIFNγ during permeabilization with 0.1% saponin. A mean of 10,000 of each T cell subset was analyzed in each sample. Background activation obtained with CD8 + T cells nonpulsed with any peptide (0-0.3%) was subtracted.
In vivo cross-priming assay with 3t3-rIPK3-oVa necroptotic cells
The crosspriming assay was performed as described in (Yatim et al., 2015) . In brief, 3T3RIPK3OVA cells were harvested and resuspended in complete media at 5 × 10 6 cell/ ml. Dimerizer was added at 1 µM, and cells were incubated for 10 min at 37°C, gently flicking the tube every 2 min. Icecold PBS was added, and cells were washed, counted, and resuspended in cold PBS at 10 7 cells/ml and were kept on ice until injections. 100 µl of cells (10 6 cells) were injected intradermally in the flanks of the mice. 9 d later, the spleen and the draining lymph node (inguinal lymph node) were harvested, pooled, and stained for surface markers and K b MHC I tetramers specific for OVA presented in the context of MHC class I molecules.
tumor growth experiments eG7 tumor assay. Sec22b +/+ and Sec22b −/− mice were in jected intradermally with 10 6 EG7 tumor cells in 100 µl of cold PBS. Tumor cells for injection were recovered from log phase in vitro growth and were injected into the right flank skin of recipient mice. Tumors were clearly visible after 7 d and grew progressively, in an encapsulated fashion. Tumor growth was measured each day and followed until d 20 or when the size reached 1,000 mm 3 . Afterward, mice were eu thanized. 10 mice were used for both Sec22b +/+ and Sec22b −/− groups. To measure CD8 + T cell responses, blood samples were collected from mice 7 d after tumor injections, RBCs were lysed three times with RBC lysis buffer (SigmaAldrich), and the nonlysed cells were stained with a couple of K b MHC I tetramers specific for OVA presented in the context of MHC class I molecules (provided by the Albert group).
Mca101 oVa-secreting tumor assay and immunotherapy. Sec22b +/+ and Sec22b −/− mice were injected intradermally with 5 × 10 5 MCA101 OVAsecreting tumor cells in 100 µl of cold PBS. Tumor cells for injection were recovered from log phase in vitro growth and were injected into the right flank skin of recipient mice. Tumors were clearly visible after 4-5 d and grew progressively, in an encapsulated fashion. Tumor growth was measured every 2 d and was followed until d 30 or until the size reached 1,000 mm 3 . Afterward, mice were euthanized. 10-15 mice were used for each condi tion. Anti-PDL1 treatment consisted of five injections of 200 µg of antibody, delivered on d 0, 3, 6, 9, and 12, i.p. Cold PBS was injected to control groups. Mice were bled on d 13 after tumor injections, and RBCs were lysed as described in the previous section. The unrelated protein human serum al bumin, the peptide SII NFE KL, and the PMA/ionomycin were given to nonlysed cells and loaded in MHC I by blood antigenpresenting cells. Subsequent restimulation of OVA specific T cells was analyzed by IFNγ ELISpot kit, following the manufacturer's instructions.
IFn-γ production by cd8 + t cells from spleen and tumors obtained from Mca101-oVa-injected mice. Mice were in oculated with MCA101OVA tumors and received anti-PD1 treatment as mentioned above. At d 13, mice were sacrificed, and spleens and tumors were collected and pro cessed with Liberase and DNase I, as described. CD8 + T cells from spleens were isolated with EasySep Mouse Naive CD8 + T Cell isolation kit, following manufacturer's instruction, and were loaded with Cell Trace Violet (Invitrogen). In addition, total tumor cells were loaded with Cell Trace Violet. 500,000 cells from both spleens and tumors were plated per well in a flat, 96well plate coated with CD3 (Miltenyi Biotec) at 1 mg/ml with increasing concentrations of CD28 (0, 0.25, 0.5, and 1 mg/ml). After 72 h, plated T cells were treated with Brefeldin A (5 µg/ml; BioLegend) for 3 h to enhance intra cellular IFNγ accumulation. Subsequently, intracellular staining for IFNγ, as well as CD3, CD4, CD8, and PD1 staining, was performed. analysis of oVa-specific cd8 + t cells in Sec22b +/+ and Sec22b −/− mice. Mice were immunized in the footpad with 50 μl of IFACpG (25 µg per mouse)SII NFE KL (100 µg per mouse). 8 d later, draining popliteal and inguinal lymph nodes were collected and smashed with a cell strainer and subse quently filtered. 500,000 cells were plated per well, and IFNγ ELISpot analysis was performed as described earlier using OVA and SII NFE KL as antigens for restimulation. Statistical analysis. All statistical analyses were performed with Prism 7 (GraphPad Software). Pvalues, as well as statis tical tests, are detailed in the figure legends. online supplemental material Fig. S1 shows the phenotypic characterization of immune cell subsets from Sec22b +/+ and Sec22b −/− mice, as well as the expression of costimulatory molecules upon treatment with LPS, TNF, and IFNγ in DCs from the aforementioned mice. It relates to Fig. 1. Fig. S2 comprises information re garding the immunization of Sec22b +/+ and Sec22b −/− mice to analyze endogenous responses, as well as the phenotypic analysis of putative crosspresenting, migratory and resident DCs. It relates to Fig. 3. Fig. S3 includes a correlative analysis of tumor growth and T cell responses and of the different controls regarding the functionality of CD8 + T cells from Sec22b +/+ and Sec22b −/− mice.
